2025 Integrated Report
View or Download
-
Board of Directors
-
Group Executive Committee
-
Financial Results
-
Integrated Reporting
-
Sustainability Documents
-
Stephen Saad
(61) -
Sean Capazorio
(60) -
Reginald Haman
(51) -
Kuseni Dlamini
(57) -
Ben Kruger
(66) -
Linda de Beer
(55) -
Neo Dongwana
(53) -
Themba Mkhwanazi
(55) -
Chris Mortimer
(63) -
Yvonne Muthien
(68) -
David Redfern
(59) -
Raeesa Khan
(34)
Stephen Saad (61)
Group Chief Executive
Qualifications:
Appointed:
Classification:
CA(SA), PhD (Commerce) Honoris Causa
January 1999
Executive director
Further Information
Stephen is a founding shareholder of the Aspen Group and his responsibilities include strategic positioning and global transactions, geographic expansion and product diversification of Aspen in developed and emerging markets as a leading multinational pharmaceutical company.
Sean Capazorio (60)
Group Chief Financial Officer
Qualifications:
Appointed:
Classification:
CA(SA), Advanced Taxation Certificate (UNISA)
January 2022
Executive director
Further Information
Sean is responsible for the strategic and financial well-being of the Group and all the Group’s finance functions across Aspen’s businesses.
Reginald Haman (51)
Qualifications:
Appointed:
Classification:
MBA, PGDBA, ND, NHD, Graduate Diploma in Company Direction
March 2024
Executive director
Further Information
Reginald leads Aspen’s Group enablement, shared services, and governance functions, including technology, people, and strategic business processes.
He is an independent non-executive director of the Institute of Directors of Southern Africa and Sasria SOC Ltd. Reginald serves as a member of the Social & Ethics Committee.
Kuseni Dlamini (57)
Qualifications:
Appointed:
Classification:
MPhil (Oxon), BSocSci (Hons) (Natal), Global Leadership for the 21st Century Programme (Harvard), Foundations for Leadership in the 21st Century (Yale)
April 2012
Independent non-executive, Board Chair
Further Information
Kuseni previously served as Chair of Massmart Holdings Limited and Times Media Group Limited and as well as Chief Executive Officer of Old Mutual South Africa and Emerging Markets. He brings a wealth of economic and business skills to the Board, having previously held positions as the head of Anglo American South Africa and Executive Chair of Richards Bay Coal Terminal Company.
Kuseni is the former Chair of the South African National Parks and a former member of the Global Agenda Council on Economic Growth and Poverty Alleviation formed by the World Economic Forum. He is active in academic and professional bodies, which include the Council of the University of Pretoria, the South African Institute of International Affairs, and the advisory boards of the Gordon Institute of Business Science and Common Purpose.
Kuseni is a member of the Remuneration & Nomination Committee and the Social & Ethics Committee.
Ben Kruger (66)
Qualifications:
Appointed:
Classification:
BCom (Hons), CA(SA), Advanced Programme in Management (Harvard Business School)
April 2019
Lead independent non-executive
Further Information
Ben joined Standard Corporate and Merchant Bank in 1985 and, after having fulfilled various leadership roles in corporate and investment banking, was appointed Chief Executive of Standard Bank Corporate and Investment Banking in 2001. In March 2013, Ben was appointed as Co-Chief Executive Officer of the Standard Bank Group Limited, and he retired from The Standard Bank Group on 31 December 2018. He currently serves as a Non-executive director on the boards of Standard Bank Group Limited and The Standard Bank of SA Limited and as a Non-executive director on the board of the JSE Limited. He is a member of the Institute of Directors of Southern Africa and served on the board of the International Institute of Finance.
Ben is also a Member, and serves as Deputy Chair of the Council for the University of Pretoria.
Linda de Beer (55)
Qualifications:
Appointed:
Classification:
CA(SA), MCom (Tax), CD(SA)
July 2018
Independent non-executive
Further Information
Linda has 15 years’ experience as an independent non-executive director on JSE listed boards. She currently serves on the boards of Momentum Group, Momentum Metropolitan Life Limited and Shoprite Holdings Limited. She was previously a member of numerous South African and international standard setting, oversight and corporate governance structures, including the King Committee, the JSE’s Financial Reporting Investigation Panel (Chair), the International Public Interest Oversight Board (Chair), and the International Valuations Standards Council (based in London).
Linda serves as the Chair of the Remuneration & Nomination Committee and is a member of the Audit & Risk Committee.
Neo Dongwana (53)
Qualifications:
Appointed:
Classification:
CA(SA), B.Com (Hons), MCom
March 2024
Independent non-executive
Further Information
Neo currently serves as a non-executive director on the board of Nedbank Group Limited and Vukile Property Limited. She previously served as a Nonexecutive director and Chair of Barloworld Limited and the Takeover Regulation Panel and has held positions on various listed and unlisted boards across multiple industries and jurisdictions. Additionally, she was a member of the Education Committee of the Independent Regulatory Board for Auditors and the Financial Services Tribunal.
She is also a member of the African Women Chartered Accountants. Neo serves as a member of the Audit & Risk Committee.
Themba Mkhwanazi (55)
Qualifications:
Appointed:
Classification:
B.Eng (Hons)
April 2019
Independent non-executive
Further Information
Themba was appointed as the Chief Executive Officer of Kumba Iron Ore Limited, a member of the Anglo American Plc Group, in September 2016. Prior to this appointment, he held several senior executive positions at various companies, including Anglo American Coal South Africa, Rio Tinto Technology and Innovation, Rio Tinto Australia, and Huntsman Tioxide Southern Africa.
Themba is a member of the Remuneration & Nomination Committee.
Chris Mortimer (63)
Qualifications:
Appointed:
Classification:
BA, LLB
January 1999
Non-executive
Further Information
Chris has been a full-time practicing attorney since 1988 and has substantial legal and commercial expertise. His intimate knowledge of the Group, its business operations and governance processes have been of immense benefit to Aspen over the years and he continues to serve the Board as a trusted adviser. As Chris’s firm is intermittently called upon to provide legal advice to the Group, he is classified as a non-independent non-executive director.
Yvonne Muthien (68)
Qualifications:
Appointed:
Classification:
D.Phil (Oxon), MA, BA (Hons), Leadership Financial Organizations, Harvard Business School
December 2021
Independent non-executive
Further Information
Yvonne currently serves as Chairperson of the Rhodes Food Group, and Chair of Mavovo Capital, as well as an independent non-executive director on the boards of the SA Reserve Bank and the SA SME Fund.She was also Chair of Bankserv and Chair of the Sasol Foundation, and non-executive director of Thebe Investment Corporation.
Yvonne previously served as Chief Executive: Group Services at Sanlam and executive director of Sanlam Ltd as well as non-executive director of Santam, Sanlam Investments and Sanlam Investment Management. Preceding that she was Vice President of Coca-Cola Africa based in London and a Group Executive at the MTN Group Ltd.
She also formerly served as a nonexecutive director of Aurecon, Sentech, MTN Nigeria, the SABC, and Transnet. Yvonne serves as the Chair of the Social & Ethics Committee and is a member of the Audit & Risk Committee.
David Redfern (59)*
Qualifications:
Appointed:
Classification:
BSc (Hons), CA
February 2015
Non-executive * British
Further Information
David was appointed President Corporate Development of GSK in May 2008 and is responsible for business development and strategic planning. He has, in this role, assisted GSK in numerous bolt-on acquisitions, disposals and joint ventures, including the creation of Haleon plc, the world-leading consumer healthcare company, through the combination of GSK’s consumer healthcare business firstly with Novartis’s business and subsequently in 2019 with Pfizer’s business. He is a member of GSK’s Corporate Executive Team and reports to the CEO. Prior to holding this position, he was responsible for the leadership of GSK’s business in Northern Europe from 2005 to 2008 and Central and Eastern Europe from 2002 to 2005. He joined Glaxo in 1994 in finance and progressed through a series of finance roles before becoming Finance Director of the European business in 1999. In addition to his current role, David is Chair of ViiV Healthcare Limited. ViiV is a joint venture between GSK, Pfizer and Shionogi, and focuses specifically on the research, development and global commercialisation of medicines to treat HIV/Aids.
Raeesa Khan (34)
Qualifications:
Appointed:
Classification:
LLB
January 2024
Group Company Secretary
Further Information
Raeesa Khan, in her capacity as Group Company Secretary, will take on governance oversight responsibility and the link between the Group Executive Committee and Aspen’s Board of Directors.
-
Stephen Saad
(61) -
Gus Attridge
(63) -
Sean Capazorio
(60) -
Lorraine Hill
(62) -
Reginald Haman
(51) -
Samer Kassem
(50) -
Pauline Macdonald
(48) -
Trevor Ziman
(54) -
Chris Botha
(46) -
Raeesa Khan
(34) -
Stavros Nicolaou
(59) -
Carnie van der Linde
(56)
Stephen Saad (61)
Qualifications:
Appointed:
Classification:
CA(SA), PhD (Commerce) Honoris Causa
January 1999
Group Chief Executive
Responsibilities
Stephen is a founding shareholder of the Aspen Group, and his responsibilities include strategic positioning and global transactions, geographic expansion and product diversification of Aspen in developed and emerging markets as a leading multinational pharmaceutical company.
Gus Attridge (63)
Qualifications:
Appointed:
Classification:
CA(SA)
January 1999
Group Chief Advisor
Responsibilities
Gus is a founding shareholder of Aspen and is responsible for providing insight and advice on strategic matters.
Sean Capazorio (60)
Qualifications:
Appointed:
Classification:
CA(SA), Advanced Taxation Certificate (UNISA)
January 1999
Group Chief Financial Officer
Responsibilities
Sean is responsible for the strategic and financial well-being of the Group and for all the Group’s finance functions across Aspen’s businesses.
Lorraine Hill (62)
Qualifications:
Appointed:
Classification:
BPharm
April 2021
Group Chief Operations Officer
Responsibilities
Lorraine is responsible for multiple operational areas of the business, including strategic manufacturing, pharmaceutical affairs, new product development and strategic procurement.
Reginald Haman (51)
Qualifications:
Appointed:
Classification:
MBA, PGDBA, ND, NHD, Graduate Diploma in Company Direction
April 2021
Group Chief Corporate Officer
Responsibilities
Reginald leads Aspen’s Group enablement, shared services, and governance functions, including technology, people, and strategic business processes.
He joined the Social & Ethics Committee in September 2020 and was appointed as Executive director in March 2024.
Samer Kassem (50)
Qualifications:
Appointed:
Classification:
CMA, CFM, CBM, MBA
April 2021
Chief Executive Officer, Aspen Global Incorporated
Further Information
Samer leads and directs international operations; oversees, implements and executes all global Commercial Pharmaceuticals transactions.
Pauline Macdonald (48)
Qualifications:
Appointed:
Classification:
BSc (Hons) Forensic & Analytical Chemistry
April 2024
Group Executive: Supply Chain
Responsibilities
Pauline oversees international supply, quality and regulatory functions and drives Group Supply Chain standardisation, automation.
Trevor Ziman (54)
Qualifications:
Appointed:
Classification:
CA(SA)
April 2021
Regional Chief Executive Officer, Asia Pacific
Responsibilities
Trevor implements strategy, performance delivery and trade across the Asia Pacific Commercial Pharmaceutical businesses and leads transactional activity in the region.
Chris Botha (46)
Qualifications:
Appointed:
Classification:
CA(SA), ACMA, CGMA, Adv.Dip (Tax)
April 2024
Group Executive: Finance (Manufacturing
and Commercial Pharma)
Responsibilities
Chris is responsible for the overall financial management and oversight of Aspen’s commercial and manufacturing businesses and the Group’s Holdings business unit.
Raeesa Khan (34)
Qualifications:
Appointed:
Classification:
LLB
January 2024
Group Company Secretary
Further Information
Raeesa Khan, in her capacity as Group Company Secretary, will take on governance oversight responsibility and the link between the Group Executive Committee and Aspen’s Board of Directors.
Stavros Nicolaou (59)
Qualifications:
Appointed:
Classification:
B.Pharm, FPS (SA), PhD (Medicine) Honoris Causa
April 2021
Group Senior Executive Strategic Trade
Responsibilities
Stavros initiates business development opportunities and is also key to the building and maintenance of strategic relations within industry and with all of Aspen’s stakeholders.
Carnie van der Linde (56)
Qualifications:
Appointed:
Classification:
Bachelor of Dental Science (BDS)
October 2022
Senior Group Executive: Commercial (International Regions)
Responsibilities
Carnie develops and implements the Commercial Pharmaceuticals strategy and performance delivery across the Group’s international regions.
Annual Results
